Overview
Scala Biodesign has raised $16 million in a Series A financing round, increasing its total funding to $21.5 million since its inception in 2022. The funding, aimed at enhancing its AI-driven protein design platform, was led by Grove Ventures with participation from TLV Partners, Deep Insight, the Israel Innovation Authority, and others.
Products
Loading...
Recent Deals
Investors: Grove Ventures, TLV Partners, Deep Insight, Israel Innovation Authority
Scala Biodesign has raised $16 million in a Series A financing round, increasing its total funding to $21.5 million since its inception in 2022. The funding, aimed at enhancing its AI-driven protein design platform, was led by Grove Ventures with participation from TLV Partners, Deep Insight, the Israel Innovation Authority, and others.